<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121654</url>
  </required_header>
  <id_info>
    <org_study_id>ITA-SCS1</org_study_id>
    <nct_id>NCT00121654</nct_id>
  </id_info>
  <brief_title>Spinal Cord Stimulation (SCS) in Refractory Angina</brief_title>
  <official_title>Randomized Study on SCS for the Treatment of Refractory Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at assessing safety and efficacy of Spinal Cord Stimulation (SCS) for the&#xD;
      treatment of refractory angina pectoris in a single blind, prospective, multicenter study.&#xD;
&#xD;
      Sixty patients with refractory angina with new SCS device implantation will be randomized to&#xD;
      one of three treatment groups:&#xD;
&#xD;
        -  paresthesic SCS;&#xD;
&#xD;
        -  subliminal SCS;&#xD;
&#xD;
        -  low (non effective) stimulation (control).&#xD;
&#xD;
      Clinical follow-up will be done at 1 and 3 months. Control group patients will then be&#xD;
      randomized to paresthesic SCS or subliminal SCS for another 3 months and the 2 groups will be&#xD;
      reassessed at 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the study is to assess safety and efficacy of Spinal Cord Stimulation (SCS) for the&#xD;
      treatment of refractory angina pectoris in a single blind, prospective, multicenter study.&#xD;
      The study also assesses whether subliminal SCS may be as effective as paresthesic SCS in&#xD;
      these patients.&#xD;
&#xD;
      Sixty consecutive patients with refractory angina with a new SCS device implantation will be&#xD;
      randomized to one of three treatment groups:&#xD;
&#xD;
        -  paresthesic SCS (group 1);&#xD;
&#xD;
        -  subliminal SCS (75-80% of paresthesic threshold; group 2);&#xD;
&#xD;
        -  low stimulation, consisting of an hour of SCS a day at 0.05 mV intensity, which does not&#xD;
           have any significant stimulator effect (sham stimulation, group 3).&#xD;
&#xD;
      Study Procedure&#xD;
&#xD;
      Medical history, clinical data, drug therapy, Angina Canadian Cardiovascular Society (CCS)&#xD;
      classification, Seattle Angina Questionnaire (SAQ), quality of life estimation by EuroQoL&#xD;
      scale, detailed evaluation of angina attacks (frequency, intensity, duration of episodes;&#xD;
      nitrates assumption) according to a structured diary, number of hospitalizations, emergency&#xD;
      room (ER) admissions and cardiological visits in the previous 6 months and treadmill exercise&#xD;
      stress test results will be obtained at the baseline visit.&#xD;
&#xD;
      Patients fulfilling inclusion criteria will undergo SCS implant. During the implant,&#xD;
      stimulation tests will be performed to check paresthesic coverage of angina pain chest area.&#xD;
&#xD;
      Patients with adequate paresthesias will be randomized to one of the 3 groups. Follow-up&#xD;
      visits will be performed at 1, 3, 6, and 12 months after the SCS implant. Drug therapy will&#xD;
      not be changed at least during the first 3 months.&#xD;
&#xD;
      Patients assigned to group 2 (subliminal SCS) and those assigned to group 3 (sham SCS) will&#xD;
      be blinded about the assigned treatment.&#xD;
&#xD;
      After the 3 months group 3, patients will be randomized to group 1 or group 2 and reassessed&#xD;
      at 6-month follow-up (comparison between paresthesic versus subliminal SCS).&#xD;
&#xD;
      The controlled study will end at the 6-month follow-up, when each investigator will decide&#xD;
      for the best stimulation for individual patients. Every patient will then be followed until&#xD;
      12 months from SCS implant.&#xD;
&#xD;
      Clinical assessment will be done at each follow-up visit. Exercise stress test results will&#xD;
      be repeated at 3-, 6- and 12-month follow-up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of angina symptoms</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>improvement of quality of life</measure>
    <time_frame>1, 3, 6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of exercise induced myocardial ischemia</measure>
    <time_frame>3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of adverse events and complications</measure>
    <time_frame>0, 1, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paresthesic SCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subliminal SCS (75-80% of paresthesic threshold)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>low stimulation, consisting of an hour of SCS a day at 0.05 mV intensity, which does not have any significant stimulator effect (sham stimulation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spinal cord stimulation</intervention_name>
    <description>Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable angina pectoris refractory to optimal medical therapy, with at least 10 angina&#xD;
             episodes in the three weeks previous SCS implant;&#xD;
&#xD;
          -  Documentation of coronary artery disease and reversible myocardial ischaemia;&#xD;
&#xD;
          -  Patient is not a candidate for or refuses surgical or percutaneous coronary&#xD;
             revascularization;&#xD;
&#xD;
          -  Availability for follow-up visits;&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe spinal cord diseases that prevent the catheter positioning in the epidural&#xD;
             space;&#xD;
&#xD;
          -  No paresthesic coverage of angina pain area during SCS;&#xD;
&#xD;
          -  Unstable angina pectoris;&#xD;
&#xD;
          -  Female patients in fertile age;&#xD;
&#xD;
          -  Enrolment in other studies;&#xD;
&#xD;
          -  Need for anticoagulant therapy;&#xD;
&#xD;
          -  Patients needing diathermy treatment;&#xD;
&#xD;
          -  Life expectancy &lt;12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaetano A Lanza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of the Sacred Heart</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gaetano A Lanza, MD</last_name>
    <phone>+390630154187</phone>
    <email>g.a.lanza@rm.unicatt.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto di Cardiologia - Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaetano A Lanza, MD</last_name>
      <phone>+390630154187</phone>
      <email>g.a.lanza@rm.unicatt.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>July 14, 2005</study_first_submitted>
  <study_first_submitted_qc>July 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>March 9, 2009</last_update_submitted>
  <last_update_submitted_qc>March 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gaetano Antonio Lanza</name_title>
    <organization>Università Cattolica del Sacro Cuore, Roma</organization>
  </responsible_party>
  <keyword>Angina pectoris</keyword>
  <keyword>Spinal cord stimulation</keyword>
  <keyword>Refractory angina pectoris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

